Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
Titel:
Neoadjuvant anthracycline-based (5-FEC) or anthracycline-free (docetaxel/carboplatin) chemotherapy plus trastuzumab and pertuzmab in HER2 + BC patients according to their TOP2A: a multicentre, open-label, non-randomized phase II trial
Auteur:
Ginzac, Angeline Molnar, Ioana Durando, Xavier Motte Rouge, Thibault De La Petit, Thierry D’hondt, Véronique Campone, Mario Bonichon-Lamichhane, Nathalie Venat Bouvet, Laurence Levy, Christelle Augereau, Paule Pistilli, Barbara Arsene, Olivier Jouannaud, Christelle Nguyen, Suzanne Cayre, Anne Tixier, Lucie Mahier Ait Oukhatar, Céline Nabholtz, Jean-Marc Penault-Llorca, Frédérique Mouret-Reynier, Marie-Ange